Lonza buys InterHealth Nutraceuticals for up to €267m


Related tags Nutrition Medicine Management Lonza

Swiss ingredients and pharma giant Lonza has agreed to pay up to $300 million (€267m) for Californian nutrient specialist InterHealth Nutraceuticals.

Lonza gains a suite of about 15 branded nutrients including its marquee collagen offering, UC-II.

“We are looking forward to welcoming the highly capable team to our Lonza family,”​ said Lonza CEO Richard Ridinger in a statement.

“They nicely complement our offerings and will be joining us in our quest to becoming the world’s leading and most-trusted supplier to the pharmaceutical, biotech and specialty ingredients markets. Lonza will be able to harness the proven management and branding capabilities and leverage them to a global level.”

The payment is split between an up-front payment and an earn-out payment.

Lonza said InterHealth – formerly owned by Kainos Capital - would continue to operate in the same premises with the same staff.

Otgher InterHealth offering include Meratrim for weight management; Relora for stress management; ChromeMate and Zychrome for blood sugar and insulin control and CardiaSlim for  cholesterol management.

Related news

Show more

Related products

show more

New Study for Female Athletes

New Study for Female Athletes

Content provided by Gencor | 19-Oct-2023 | Product Brochure

In a recent clinical trial backing its ingredient Libifem® for improved muscle strength, power, endurance and body composition with a females-only popluation...

The Art of Organic Certification

The Art of Organic Certification

Content provided by FoodChain ID | 09-Oct-2023 | White Paper

The organic food market has experienced remarkable growth over the past decade, providing a major opportunity for food brands and manufacturers to tap...

Discover how to enhance ingredient functionality

Discover how to enhance ingredient functionality

Content provided by Lonza | 04-Oct-2023 | Product Brochure

Consumer demand for capsules shows no sign of slowing down—they are the globally preferred dosage form for 50% of consumers. But in an increasingly saturated...

Related suppliers

Follow us


View more